Medical team treatment decision of immune-checkpoint inhibitor in non-small cell lung cancer

Medical team treatment decision of immune-checkpoint inhibitor in non-small cell lung cancer - Medical team treatment decision of immune-checkpoint inhibitor in non-small cell lung cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000031608

Enrollment

Registered

2018-03-12

Start date

2018-03-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 Histologically or cytologically confirmed non-small cell lung cancer 2 At least one regimen or more of chemotherapy has been performed 3 18 years-old or over 4 Patients were judged appropriate by the attending physician as subjects of immune checkpoint inhibitors 5 Whether or not there is an evaluable lesion is not required 6 Patients who have adequate organ function 7 Patients provided written imformed consent

Exclusion criteria

Exclusion criteria: 1 Patients who the physician judges unsuitable for this study 2 Patients who had pretreatment with immune checkpoint inhibitor

Design outcomes

Primary

Measure	Time frame
The correct rate of decision on 28 days after the start of administration	—

Countries

Japan

Contacts

Public ContactHidekazu Suzuki

Osaka Habikino Medical Center Department of Thoracic oncology

suzukih@opho.jp0729572121

Outcome results